Virtus LifeSci Biotech Products ETF (BBP)
| Assets | $24.89M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 400,004 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 196 |
| Open | 61.61 |
| Previous Close | 62.66 |
| Day's Range | 61.61 - 61.61 |
| 52-Week Low | 48.65 |
| 52-Week High | 69.12 |
| Beta | 0.53 |
| Holdings | 57 |
| Inception Date | Dec 17, 2014 |
About BBP
Fund Home PageThe Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is issued by Virtus Investment Partners.
Top 10 Holdings
21.56% of assets| Name | Symbol | Weight |
|---|---|---|
| Rhythm Pharmaceuticals, Inc. | RYTM | 2.55% |
| CRISPR Therapeutics AG | CRSP | 2.36% |
| Ardelyx, Inc. | ARDX | 2.15% |
| Ligand Pharmaceuticals Inc. | LGND | 2.13% |
| Ionis Pharmaceuticals, Inc. | IONS | 2.09% |
| BridgeBio Pharma, Inc. | BBIO | 2.09% |
| Moderna, Inc. | MRNA | 2.08% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 2.08% |
| Agios Pharmaceuticals, Inc. | AGIO | 2.07% |
| Legend Biotech Corporation | LEGN | 1.97% |
Performance
BBP had a total return of -3.26% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.99%.
News
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Late-stage biotech ETFs rally Monday on virus treatment hopes
Late-stage biotech exchange-traded funds were among the day's biggest gainers Monday as investors pinned their hopes on medical responses to the novel coronavirus. The ALPS Medical Breakthroughs ETF ...